Ocular manifestations of anti-neoplastic immune checkpoint inhibitor-associated Stevens-Johnson syndrome/toxic epidermal necrolysis in cancer patients

•SJS/TEN with severe ocular involvement can occur following immune checkpoint inhibitor treatment.•Causative ICIs included nivolumab, pembrolizumab, atezolizumab, durvalumab, and ipilimumab.•Poor survival of the patients due to advanced cancer stage.•Early and aggressive treatments are vital to prev...

Full description

Saved in:
Bibliographic Details
Published in:The ocular surface 2021-10, Vol.22, p.47-50
Main Authors: Ma, Kevin Sheng-Kai, Saeed, Hajirah N., Chodosh, James, Wang, Chuang-Wei, Chung, Yu-Chien, Wei, Li-Chen, Kuo, Ming-Tse, Liang, Chang-Min, Chang, John Wen-Cheng, Chung, Wen-Hung, Chen, Chun-Bing, Ma, David Hui-Kang
Format: Article
Language:English
Subjects:
Algorithm of drug causality for epidermal necrolysis
Eye
Humans
Immune checkpoint inhibitor
Immune Checkpoint Inhibitors
Neoplasms
Ocular surface grading score
Stevens-Johnson syndrome
Stevens-Johnson Syndrome - etiology
Toxic epidermal necrolysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•SJS/TEN with severe ocular involvement can occur following immune checkpoint inhibitor treatment.•Causative ICIs included nivolumab, pembrolizumab, atezolizumab, durvalumab, and ipilimumab.•Poor survival of the patients due to advanced cancer stage.•Early and aggressive treatments are vital to prevent long-term ocular complication.
ISSN:1542-0124
1937-5913
DOI:10.1016/j.jtos.2021.06.010